SK282263B6 - Imunokonjugát, spôsob jeho prípravy a farmaceutický prostriedok, ktorý ho obsahuje - Google Patents
Imunokonjugát, spôsob jeho prípravy a farmaceutický prostriedok, ktorý ho obsahuje Download PDFInfo
- Publication number
- SK282263B6 SK282263B6 SK1145-95A SK114595A SK282263B6 SK 282263 B6 SK282263 B6 SK 282263B6 SK 114595 A SK114595 A SK 114595A SK 282263 B6 SK282263 B6 SK 282263B6
- Authority
- SK
- Slovakia
- Prior art keywords
- antibody
- immunoconjugate
- mab
- fragment
- chemokine
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/582—Recycling of unreacted starting or intermediate materials
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Cell Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP94114572 | 1994-09-16 |
Publications (2)
Publication Number | Publication Date |
---|---|
SK114595A3 SK114595A3 (en) | 1997-03-05 |
SK282263B6 true SK282263B6 (sk) | 2001-12-03 |
Family
ID=8216289
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SK1145-95A SK282263B6 (sk) | 1994-09-16 | 1995-09-13 | Imunokonjugát, spôsob jeho prípravy a farmaceutický prostriedok, ktorý ho obsahuje |
Country Status (20)
Country | Link |
---|---|
US (1) | US5824782A (fr) |
EP (1) | EP0706799B1 (fr) |
JP (2) | JP3865802B2 (fr) |
KR (1) | KR100386171B1 (fr) |
CN (1) | CN1123185A (fr) |
AT (1) | ATE208633T1 (fr) |
AU (1) | AU702184B2 (fr) |
CA (1) | CA2158322C (fr) |
CZ (1) | CZ289641B6 (fr) |
DE (1) | DE69523857T2 (fr) |
DK (1) | DK0706799T3 (fr) |
ES (1) | ES2167391T3 (fr) |
HU (1) | HU221989B1 (fr) |
NO (1) | NO315976B1 (fr) |
PL (1) | PL182636B1 (fr) |
PT (1) | PT706799E (fr) |
RU (1) | RU2157701C2 (fr) |
SK (1) | SK282263B6 (fr) |
UA (1) | UA40611C2 (fr) |
ZA (1) | ZA957808B (fr) |
Families Citing this family (81)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2292760A1 (fr) * | 1997-06-04 | 1998-12-10 | Oxford Biomedica (Uk) Limited | Vecteur |
US7635687B2 (en) * | 1997-06-04 | 2009-12-22 | Oxford Biomedica (Uk) Limited | Vector system |
US7276488B2 (en) * | 1997-06-04 | 2007-10-02 | Oxford Biomedica (Uk) Limited | Vector system |
EP1037927B1 (fr) | 1997-12-08 | 2004-05-19 | Lexigen Pharmaceuticals Corp. | Proteines de fusion heterodymeres utiles en therapie immune ciblee et a une stimulation immune generale |
AU2903999A (en) * | 1998-03-12 | 1999-09-27 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | Methods and compositions of chemokine-tumor antigen fusion proteins as cancer vaccines |
NZ506877A (en) * | 1998-03-31 | 2002-04-26 | Tanabe Seiyaku Co | Benzenesulfonamide compounds useful in treating dysuria |
CA2328076C (fr) * | 1998-04-15 | 2009-10-06 | Lexigen Pharmaceuticals Corporation | Co-administration d'un inhibiteur de l'angiogenese pour renforcer la reponse immunitaire a mediation de proteine de fusion d'une cytokine d'anticorps |
CA2328081A1 (fr) * | 1998-04-17 | 1999-10-28 | Lexigen Pharmaceuticals Corporation | Amelioration des reponses immunitaires dont la mediation est assuree par une proteine de fusion anticorps-cytokine, via coadministration de cette proteine de fusion avec un inhibiteur de prostaglandine |
US6869606B1 (en) | 1999-02-22 | 2005-03-22 | Millennium Pharmaceuticals, Inc. | Biotinylated-chemokine antibody complexes |
AU5617900A (en) * | 1999-06-17 | 2001-01-09 | Robert C. Gallo | Chimeric chemokine-antigen polypeptides and uses therefor |
GB9915074D0 (en) * | 1999-06-28 | 1999-08-25 | Cortecs Plc | Ligand-binding composition |
SK782002A3 (en) | 1999-07-21 | 2003-08-05 | Lexigen Pharm Corp | FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens |
MXPA02001417A (es) | 1999-08-09 | 2002-08-12 | Lexigen Pharm Corp | Complejos multiples de citosina-anticuerpo. |
AU1290001A (en) * | 1999-11-18 | 2001-05-30 | Oxford Biomedica (Uk) Limited | Antibodies |
US6319675B1 (en) | 1999-11-24 | 2001-11-20 | Millennium Pharmaceuticals, Inc. | Methods for detecting and/or identifying agents which bind and/or modulate function of “bonzo” chemokine receptor |
US7208152B2 (en) * | 1999-11-24 | 2007-04-24 | Millennium Pharmaceuticals, Inc. | Antibodies for “Bonzo” chemokine receptor and therapeutic uses thereof |
ES2269366T3 (es) | 2000-02-11 | 2007-04-01 | Merck Patent Gmbh | Mejoramiento de la vida media en circulacion de proteinas de fusion basadas en anticuerpos. |
DE10019157A1 (de) * | 2000-04-18 | 2001-11-15 | Stefan Duebel | Verfahren zum Einbringen von Liganden in lebende Zellen |
KR100480985B1 (ko) * | 2000-05-19 | 2005-04-07 | 이수화학 주식회사 | 표피 성장 인자 수용체에 대한 사람화된 항체 |
US7754676B2 (en) | 2000-09-15 | 2010-07-13 | The United States Of America As Represented By The Department Of Health And Human Services | Defensin-antigen fusion proteins |
WO2002022687A2 (fr) | 2000-09-15 | 2002-03-21 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Proteines de fusion chimiokine virale-antigene tumoral |
GB0029407D0 (en) * | 2000-12-01 | 2001-01-17 | Affitech As | Product |
CN1330664C (zh) | 2001-03-07 | 2007-08-08 | 默克专利有限公司 | 用于含杂合同种型抗体部分的蛋白质的表达技术 |
US6992174B2 (en) | 2001-03-30 | 2006-01-31 | Emd Lexigen Research Center Corp. | Reducing the immunogenicity of fusion proteins |
CN100503639C (zh) | 2001-05-03 | 2009-06-24 | 默克专利有限公司 | 重组肿瘤特异性抗体及其应用 |
EP1256354A1 (fr) * | 2001-05-11 | 2002-11-13 | Schering Corporation | Methodes pour le traitement du cancer |
US20020193569A1 (en) * | 2001-06-04 | 2002-12-19 | Idec Pharmaceuticals Corporation | Bispecific fusion protein and method of use for enhancing effector cell killing of target cells |
CN100497389C (zh) | 2001-06-13 | 2009-06-10 | 根马布股份公司 | 表皮生长因子受体(egfr)的人单克隆抗体 |
US7595378B2 (en) | 2001-06-13 | 2009-09-29 | Genmab A/S | Human monoclonal antibodies to epidermal growth factor receptor (EGFR) |
DK1399484T3 (da) * | 2001-06-28 | 2010-11-08 | Domantis Ltd | Dobbelt-specifik ligand og anvendelse af denne |
GB0126378D0 (en) * | 2001-11-02 | 2002-01-02 | Oxford Biomedica Ltd | Antigen |
MXPA04005266A (es) | 2001-12-04 | 2004-10-11 | Merck Patent Gmbh | Inmunocitocinas con selectividad modulada. |
JP4212921B2 (ja) | 2002-03-29 | 2009-01-21 | 独立行政法人科学技術振興機構 | 抗体を提示するタンパク質中空ナノ粒子を用いる治療薬剤およびタンパク質中空ナノ粒子 |
US9321832B2 (en) * | 2002-06-28 | 2016-04-26 | Domantis Limited | Ligand |
US7696320B2 (en) | 2004-08-24 | 2010-04-13 | Domantis Limited | Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor |
DE60305919T2 (de) * | 2002-06-28 | 2007-01-18 | Domantis Limited, Cambridge | Dual-specifische liganden mit erhöhter halbwertszeit |
US20040110929A1 (en) * | 2002-07-12 | 2004-06-10 | Bjorn Soren E. | TF binding compound |
CA2502367C (fr) | 2002-10-16 | 2013-12-10 | Euro-Celtique S.A. | Anticorps se fixant sur des polypeptides ca 125/o772p associes a des cellules et leurs procedes d'utilisation |
US7388079B2 (en) * | 2002-11-27 | 2008-06-17 | The Regents Of The University Of California | Delivery of pharmaceutical agents via the human insulin receptor |
US7169904B2 (en) | 2002-12-17 | 2007-01-30 | Emd Lexigen Research Center Corp. | Immunocytokine sequences and uses thereof |
CA2511910A1 (fr) * | 2002-12-27 | 2004-07-15 | Domantis Limited | Ligand |
WO2004074437A2 (fr) * | 2003-02-14 | 2004-09-02 | University Of Southern California | Compositions et methodes pour immunotherapie anticancereuse |
WO2005063820A2 (fr) | 2003-12-30 | 2005-07-14 | Merck Patent Gmbh | Proteines de fusion de il-7 |
CA2552590A1 (fr) | 2004-01-05 | 2005-07-21 | Emd Lexigen Research Center Corp. | Composes de ciblage |
US7670595B2 (en) | 2004-06-28 | 2010-03-02 | Merck Patent Gmbh | Fc-interferon-beta fusion proteins |
GB2424886A (en) | 2005-04-04 | 2006-10-11 | Dxs Ltd | Polynucleotide primers against epidermal growth factor receptor and method of detecting gene mutations |
US8142781B2 (en) * | 2005-10-07 | 2012-03-27 | Armagen Technologies, Inc. | Fusion proteins for blood-brain barrier delivery |
US8741260B2 (en) * | 2005-10-07 | 2014-06-03 | Armagen Technologies, Inc. | Fusion proteins for delivery of GDNF to the CNS |
US8124095B2 (en) * | 2005-10-07 | 2012-02-28 | Armagen Technologies, Inc. | Fusion proteins for delivery of erythropoietin to the CNS |
TW200730539A (en) * | 2005-12-01 | 2007-08-16 | Domantis Ltd | Noncompetitive domain antibody formats that bind interleukin 1 receptor type 1 |
JP5959795B2 (ja) * | 2006-08-18 | 2016-08-02 | アーメイゲン・テクノロジーズ・インコーポレイテッドArmagen Technologies, Inc. | 血液脳関門送達のための物質 |
CN101173008B (zh) * | 2006-11-01 | 2011-06-22 | 复旦大学 | 一种双功能融合蛋白及其制备方法和应用 |
US20090011040A1 (en) * | 2007-05-02 | 2009-01-08 | Naash Muna I | Use of compacted nucleic acid nanoparticles in non-viral treatments of ocular diseases |
NZ580530A (en) | 2007-06-06 | 2012-04-27 | Domantis Ltd | Anti vegf polypeptides, antibody variable domains and antagonists |
EP2997976A1 (fr) | 2007-07-27 | 2016-03-23 | Armagen Technologies, Inc. | Procédés et compositions pour augmenter l'activité alpha-l-iduronidase dans le système nerveux central |
EP2853267B1 (fr) * | 2007-09-21 | 2016-12-07 | The Regents of the University of California | Interféron ciblé manifestant des activités apoptotiques et anti-tumorales puissantes |
WO2009114110A1 (fr) * | 2008-03-08 | 2009-09-17 | Immungene, Inc. | Immunothérapie avec molécules de fusion modifiées utilisées dans le cancer et les maladies inflammatoires |
US20100098693A1 (en) * | 2008-10-07 | 2010-04-22 | Pardridge William M | Compositions and methods for blood-brain barrier delivery of organophosphatases |
EP3543256A1 (fr) | 2009-01-12 | 2019-09-25 | Cytomx Therapeutics Inc. | Compositions d anticorps modifiées et leurs procédés de production et d'utilisation |
JP5873003B2 (ja) | 2009-03-18 | 2016-03-01 | アーメイゲン・テクノロジーズ・インコーポレイテッドArmagen Technologies, Inc. | IgGデコイ受容体融合タンパク質の血液脳関門送達のための組成物および方法 |
CA2759333A1 (fr) | 2009-04-22 | 2010-10-28 | Merck Patent Gmbh | Proteines de fusion a des anticorps avec des sites de liaison a fcrn modifies |
DK2485761T3 (da) | 2009-10-09 | 2019-05-06 | Armagen Inc | Fremgangsmåder og sammensætninger til øgning af iduronat-2-sulfatase-aktivitet i CNS |
UY34317A (es) | 2011-09-12 | 2013-02-28 | Genzyme Corp | Anticuerpo antireceptor de célula T (alfa)/ß |
KR102096224B1 (ko) | 2011-10-28 | 2020-04-03 | 테바 파마슈티컬즈 오스트레일리아 피티와이 엘티디 | 폴리펩티드 구축물 및 이의 용도 |
CA2857647C (fr) | 2011-12-02 | 2022-04-19 | Armagen Technologies, Inc. | Methodes et compositions pour augmenter l'activite arylsulfatase a dans le systeme nerveux central |
US9790268B2 (en) | 2012-09-12 | 2017-10-17 | Genzyme Corporation | Fc containing polypeptides with altered glycosylation and reduced effector function |
WO2014089354A1 (fr) | 2012-12-07 | 2014-06-12 | The Regents Of The University Of California | Interféron ciblant l'antigène cd138 présentant de puissantes activités apoptotiques et anti-tumorales |
CN110256560A (zh) | 2013-03-11 | 2019-09-20 | 建新公司 | 通过糖工程的位点特异性抗体-药物偶联 |
NZ713641A (en) | 2013-04-29 | 2019-08-30 | Teva Pharmaceuticals Australia Pty Ltd | Anti-cd38 antibodies and fusions to attenuated interferon alpha-2b |
US11117975B2 (en) | 2013-04-29 | 2021-09-14 | Teva Pharmaceuticals Australia Pty Ltd | Anti-CD38 antibodies and fusions to attenuated interferon alpha-2B |
WO2014194100A1 (fr) | 2013-05-29 | 2014-12-04 | The Regents Of The University Of California | Fusions anti-cspg4 et interféron utilisables en vue du traitement de tumeurs malignes |
PL3129067T3 (pl) | 2014-03-19 | 2023-05-08 | Genzyme Corporation | Specyficzne dla miejsca glikomodyfikowanie ugrupowań celujących |
UA119352C2 (uk) | 2014-05-01 | 2019-06-10 | Тева Фармасьютикалз Острейліа Пті Лтд | Комбінація леналідоміду або помалідоміду і конструкції анти-cd38 антитіло-атенуйований інтерферон альфа-2b та спосіб лікування суб'єкта, який має cd38-експресуючу пухлину |
MX2017004664A (es) | 2014-10-09 | 2017-06-30 | Genzyme Corp | Conjugados de farmacos de anticuerpos modificados mediante glicoingenieria. |
US10544199B2 (en) | 2014-10-29 | 2020-01-28 | Teva Pharmaceuticals Australia Pty Ltd | Interferon alpha 2B variants |
US10538589B2 (en) | 2015-01-14 | 2020-01-21 | Armagen Inc. | Methods and compositions for increasing N-acetylglucosaminidase (NAGLU) activity in the CNS using a fusion antibody comprising an anti-human insulin receptor antibody and NAGLU |
JP6824994B2 (ja) * | 2015-10-07 | 2021-02-03 | サングイ バイオ ピーティーワイ. エルティーディー | 血液の調製及びプロファイリング |
JP7241677B2 (ja) | 2016-07-19 | 2023-03-17 | テバ・ファーマシューティカルズ・オーストラリア・ピーティワイ・リミテッド | 抗cd47併用療法 |
JP2020535809A (ja) * | 2017-09-29 | 2020-12-10 | ナントセル,インコーポレイテッド | 抗原タンパク質及びそのための方法 |
JP2022515198A (ja) | 2018-12-19 | 2022-02-17 | アレイ バイオファーマ インコーポレイテッド | FGFRチロシンキナーゼの阻害剤としての置換ピラゾロ[1,5-a]ピリジン化合物 |
WO2020131674A1 (fr) | 2018-12-19 | 2020-06-25 | Array Biopharma Inc. | Dérivés de 7-((3,5-diméthoxyphényl)amino)quinoxaline servant d'inhibiteurs de fgfr pour le traitement du cancer |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5470571A (en) * | 1988-01-27 | 1995-11-28 | The Wistar Institute | Method of treating human EGF receptor-expressing gliomas using radiolabeled EGF receptor-specific MAB 425 |
IE63847B1 (en) * | 1989-05-05 | 1995-06-14 | Res Dev Foundation | A novel antibody delivery system for biological response modifiers |
US5112946A (en) * | 1989-07-06 | 1992-05-12 | Repligen Corporation | Modified pf4 compositions and methods of use |
US5314995A (en) * | 1990-01-22 | 1994-05-24 | Oncogen | Therapeutic interleukin-2-antibody based fusion proteins |
WO1991014438A1 (fr) * | 1990-03-20 | 1991-10-03 | The Trustees Of Columbia University In The City Of New York | Anticorps chimeriques utilisant des ligands de liaison de recepteurs a la place de leur region constante |
JPH09506761A (ja) * | 1990-11-09 | 1997-07-08 | ステファン ディー.ギリーズ | サイトカインの免疫複合体 |
CZ282603B6 (cs) * | 1991-03-06 | 1997-08-13 | Merck Patent Gesellschaft Mit Beschränkter Haftun G | Humanizované a chimerické monoklonální protilátky |
EP0603194A4 (fr) * | 1991-07-05 | 1994-12-07 | Seragen Inc | Molecules ciblees sur un recepteur du facteur de croissance epidermique, et utilisees dans le traitement de l'arthrite inflammatoire. |
ATE188874T1 (de) * | 1992-08-18 | 2000-02-15 | Centro Inmunologia Molecular | Monoklonale antikörper gegen den epidermalen wachstumsfaktorrezeptor, zellen und verfahren zur ihrer herstellung und sie erhaltende zusammensetzungen |
-
1995
- 1995-09-06 EP EP95113956A patent/EP0706799B1/fr not_active Expired - Lifetime
- 1995-09-06 DK DK95113956T patent/DK0706799T3/da active
- 1995-09-06 ES ES95113956T patent/ES2167391T3/es not_active Expired - Lifetime
- 1995-09-06 DE DE69523857T patent/DE69523857T2/de not_active Expired - Fee Related
- 1995-09-06 PT PT95113956T patent/PT706799E/pt unknown
- 1995-09-06 AT AT95113956T patent/ATE208633T1/de not_active IP Right Cessation
- 1995-09-08 AU AU30533/95A patent/AU702184B2/en not_active Ceased
- 1995-09-11 JP JP23283295A patent/JP3865802B2/ja not_active Expired - Fee Related
- 1995-09-13 SK SK1145-95A patent/SK282263B6/sk unknown
- 1995-09-14 CN CN95116279A patent/CN1123185A/zh active Pending
- 1995-09-14 CZ CZ19952375A patent/CZ289641B6/cs not_active IP Right Cessation
- 1995-09-14 UA UA95094164A patent/UA40611C2/uk unknown
- 1995-09-14 CA CA002158322A patent/CA2158322C/fr not_active Expired - Fee Related
- 1995-09-15 PL PL95310493A patent/PL182636B1/pl not_active IP Right Cessation
- 1995-09-15 US US08/528,523 patent/US5824782A/en not_active Expired - Fee Related
- 1995-09-15 NO NO19953650A patent/NO315976B1/no not_active IP Right Cessation
- 1995-09-15 KR KR1019950030385A patent/KR100386171B1/ko not_active IP Right Cessation
- 1995-09-15 ZA ZA957808A patent/ZA957808B/xx unknown
- 1995-09-15 HU HU9502711A patent/HU221989B1/hu not_active IP Right Cessation
- 1995-09-15 RU RU95115976/14A patent/RU2157701C2/ru not_active IP Right Cessation
-
2005
- 2005-11-17 JP JP2005332965A patent/JP2006117684A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
ES2167391T3 (es) | 2002-05-16 |
NO953650L (no) | 1996-03-18 |
JP3865802B2 (ja) | 2007-01-10 |
RU2157701C2 (ru) | 2000-10-20 |
AU702184B2 (en) | 1999-02-18 |
PL182636B1 (pl) | 2002-02-28 |
CA2158322A1 (fr) | 1996-03-17 |
JP2006117684A (ja) | 2006-05-11 |
CN1123185A (zh) | 1996-05-29 |
JPH0899901A (ja) | 1996-04-16 |
HUT75836A (en) | 1997-05-28 |
UA40611C2 (uk) | 2001-08-15 |
US5824782A (en) | 1998-10-20 |
HU9502711D0 (en) | 1995-11-28 |
KR100386171B1 (ko) | 2003-08-21 |
EP0706799A2 (fr) | 1996-04-17 |
DK0706799T3 (da) | 2002-02-25 |
CA2158322C (fr) | 2009-06-16 |
HU221989B1 (hu) | 2003-03-28 |
EP0706799B1 (fr) | 2001-11-14 |
KR960010023A (ko) | 1996-04-20 |
NO953650D0 (no) | 1995-09-15 |
PL310493A1 (en) | 1996-03-18 |
DE69523857T2 (de) | 2002-06-13 |
SK114595A3 (en) | 1997-03-05 |
ZA957808B (en) | 1996-05-07 |
NO315976B1 (no) | 2003-11-24 |
ATE208633T1 (de) | 2001-11-15 |
PT706799E (pt) | 2002-05-31 |
AU3053395A (en) | 1996-03-28 |
CZ237595A3 (en) | 1996-04-17 |
CZ289641B6 (cs) | 2002-03-13 |
DE69523857D1 (de) | 2001-12-20 |
EP0706799A3 (fr) | 1996-12-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SK282263B6 (sk) | Imunokonjugát, spôsob jeho prípravy a farmaceutický prostriedok, ktorý ho obsahuje | |
RU2129018C1 (ru) | Иммуноконьюгат, способ получения иммуноконьюгата и фармацевтическая композиция | |
CA2095836C (fr) | Immunoconjugues de la cytokine | |
US5650150A (en) | Recombinant antibody cytokine fusion proteins | |
AU2001275246B2 (en) | T cell receptor fusions and conjugates and methods of use thereof | |
WO1995009917A1 (fr) | Anticorps bispecifiques et tetravalents, obtenus par genie genetique | |
KR20010022075A (ko) | T세포활성화를유도하는슈퍼항원접합체에의한표적세포의세포용해 | |
IE63186B1 (en) | Cloned genes encoding IG-CD4 fusion proteins and the use thereof | |
EP1107989A2 (fr) | Expression et exportation d'angiostatine et d'endostatine sous forme d'immunofusines | |
US20100015661A1 (en) | Antibody-rnase-conjugate | |
CA2294223C (fr) | Immunotoxines anti-cd40l servant a traiter des maladies | |
Burbage et al. | Ricin fusion toxin targeted to the human granulocyte-macrophage colony stimulating factor receptor is selectively toxic to acute myeloid leukemia cells | |
Sun et al. | Antitumour activity of a chimeric antibody against the leucocyte antigen CD48 |